PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch(International Association for the Study of Lung Cancer), Abigail McElhinny(Human Genome Sciences (United States)), Dave Stanforth(Agilent Technologies (United States)), James Ranger‐Moore(Roche (United States)), Malinka Jansson(Agilent Technologies (United States)), Karina Kulangara(Agilent Technologies (United States)), William D. Richardson(Roche (United States)), Penny Towne(Roche (United States)), Debra Hanks(Agilent Technologies (United States)), Bharathi Vennapusa(Roche (United States)), Amita Mistry(Roche (United States)), Rasika Kalamegham(American Association For Cancer Research), Steve Averbuch(Bristol-Myers Squibb (United States)), James Novotny(Bristol-Myers Squibb (United States)), Eric H. Rubin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ian McCaffery(Silvus Technologies (United States)), J. Andrew Williams, Jill Walker(AstraZeneca (United Kingdom)), John Longshore(Carolinas Healthcare System), Ming‐Sound Tsao(University Health Network), Keith M. Kerr(Aberdeen Royal Infirmary)
Cited by 1,246Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis